Strategic Partners A/S — Director's Dealing 2020

Mar 3, 2020

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

**Orphazyme A/S

Company announcement**                                                                                       

No. 23/2020                                                                                                          

Company Registration No. 32266355

Copenhagen, Denmark, March 3, 2020 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:

1 Details of the Reporting Person / Closely Associated Person

a) Name

Kim Stratton

2 Reason for the notification

a) Position/status

Chief Executive Officer

b) Initial notification/Amendment

Initial notification

3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

Orphazyme A/S

b) LEI code

54930025OZD2GGSQ7L42

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument and identification code

Shares

ISIN DK0060910917

b) Nature of the transaction

Purchase of shares

c) Price(s) and volume(s)

Price (s)		Volume(s)
DKK	98.00	118
DKK	98.00	250
DKK	98.00	250
DKK	98.00	121
DKK	97.80	330
DKK	98.20	291
DKK	97.80	200
DKK	98.00	233
DKK	98.00	209
DKK	98.00	88
DKK	98.00	57
DKK	98.00	43
DKK	98.00	32
DKK	98.00	174
DKK	98.00	117
DKK	98.60	297
DKK	99.00	150
DKK	99.00	142
DKK	99.00	285
DKK	99.00	330
DKK	99.20	300
DKK	99.20	254
DKK	99.20	93
DKK	99.60	470
DKK	99.60	55
DKK	99.80	270
DKK	99.80	61
DKK	99.80	221
DKK	99.80	109
DKK	99.20	76
DKK	99.60	101
DKK	99.80	95
DKK	99.60	323
DKK	99.40	200
DKK	99.40	116
DKK	99.60	305
DKK	99.60	39
DKK	99.80	103
DKK	99.80	47
DKK	98.80	307
DKK	99.60	188
DKK	99.00	50

d) Aggregated information

Aggregated volume: 7,500

Aggregated price: DKK 741,643.40

Price per share (volume weighted average): DKK 98.885787

e) Date of the transaction

28 February 2020 between 12:59 and 14:00 UTC

f) Place of the transaction

Nasdaq Copenhagen A/S - XCSE

For additional information, please contact

Orphazyme A/S

Anders Vadsholt, CFO                                  +45 28 98 90 55

About Orphazyme A/S 

Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com. 

Forward-looking statement 

This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.  

Attachment

• 23-2020 Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities